The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 08, 2009
Filed:
Jul. 25, 2007
Percy H. Carter, Princeton, NJ (US);
John V. Duncia, Newtown, PA (US);
Boguslaw M. Mudryk, East Windsor, NJ (US);
Michael E. Randazzo, East Windsor, NJ (US);
Zili Xiao, West Windsor, NJ (US);
Michael G. Yang, Narbeth, PA (US);
Rulin Zhao, Pennington, NJ (US);
Percy H. Carter, Princeton, NJ (US);
John V. Duncia, Newtown, PA (US);
Boguslaw M. Mudryk, East Windsor, NJ (US);
Michael E. Randazzo, East Windsor, NJ (US);
Zili Xiao, West Windsor, NJ (US);
Michael G. Yang, Narbeth, PA (US);
Rulin Zhao, Pennington, NJ (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
The present invention provides a novel antagonist or partial agonists/antagonist of MCP-1 receptor activity: N-((1R,2S,5R)-5-tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide, or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having an unexpected combination of desirable pharmacological characteristics. Crystalline forms of the present invention are also provided. Pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases is also an objective of this invention. The present disclosure also provides a process for preparing compounds of Formula (I), including N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide: wherein R, R,R, R, and are as described herein. Compounds that are useful intermediates of the process are also provided herein.